Drug Profile

PR 1100

Alternative Names: PR-1100

Latest Information Update: 29 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Prometheus Biosciences; Takeda
Developer Merck & Co; Takeda
Class Anti-inflammatories; Monoclonal antibodies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Inflammatory bowel diseases

Most Recent Events

29 Oct 2025 PR 1100 is still in preclinical trials for Inflammatory bowel diseases in USA (Parenteral) (Prometheus Biosciences pipeline, October 2025)
16 Jun 2023 Prometheus Biosciences has been acquired and merged into Merck & Co
11 Apr 2023 Preclinical trials in Inflammatory bowel diseases in USA (Parenteral) (Prometheus Biosciences pipeline, April 2023)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com